Cargando…
Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study
INTRODUCTION: This study explored the efficacy and safety of a serotonin‐6 receptor antagonist, masupirdine, as adjunct treatment in patients with moderate Alzheimer's disease (AD) concomitantly treated with donepezil and memantine. METHODS: The effects of masupirdine were evaluated in patients...
Autores principales: | Nirogi, Ramakrishna, Ieni, John, Goyal, Vinod Kumar, Ravula, Jyothsna, Jetta, Satish, Shinde, Anil, Jayarajan, Pradeep, Benade, Vijay, Palacharla, Veera Raghava Chowdary, Dogiparti, Dhanunjay Kumar, Jasti, Venkat, Atri, Alireza, Cummings, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157584/ https://www.ncbi.nlm.nih.gov/pubmed/35662833 http://dx.doi.org/10.1002/trc2.12307 |
Ejemplares similares
-
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
por: Nirogi, Ramakrishna, et al.
Publicado: (2022) -
Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
por: Nirogi, Ramakrishna, et al.
Publicado: (2022) -
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
por: Nirogi, Ramakrishna, et al.
Publicado: (2023) -
Parenteral nutrition: Revisited
por: Chowdary, Koneru Veera Raghava, et al.
Publicado: (2010) -
Role of Ayurveda and Yoga-Based lifestyle in the COVID-19 pandemic – A narrative review
por: Umesh, Chikkanna, et al.
Publicado: (2022)